Smoking cessation increases serum adiponectin levels in an apparently healthy Greek population

Efstathiou, Stamatis P.; Skeva, Irini I.; Dimas, Cleanthi; Panagiotou, Anna; Parisi, Cleo; Tzanoumis, Labros; Kafouri, Anna; Bakratsas, Konstantinos; Mountokalakis, Theodore D.

doi:10.1016/j.atherosclerosis.2009.01.022

Cited by 38 publications

(48 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Except for 2 studies 15,22) , 7 studies (including one intervention study) reported the results for males only 14,16,17,19,21,23,24) and 2 studies reported the results separately for males and females 18,20) . Although there were only a few studies of females, similar trends were observed in the association between smoking and adiponectin in both genders.…”

Section: Gender Differencesmentioning

confidence: 99%

“…The intervention studies used the following treatment: a 9-week pharmacological approach (150 mg sustained-release bupropion twice daily) for non-specific subjects 15) and a 6-month nonpharmacological approach to quit smoking for patients with stable angina pectoris 16) . While most of the cross-sectional studies were conducted in healthy and non-specific diseased populations recruited from general health check-ups or advertisements for the study participation 14,[17][18][19][20][22][23][24] , only one study focused on patients with coronary artery disease 21) .…”

Section: Study Designsmentioning

confidence: 99%

“…While high-molecularweight adiponectin in the circulation was used in one study 14) , this report was included in the present systematic review because the high-molecular-weight type is currently considered an active form of adiponectin 25) . The smoking status was assessed mainly by questionnaire methods, while one study simultaneously used an objective measure to evaluate the smoking exposure (e.g., cotinine) 15) .…”

Section: Measures Of Interestsmentioning

confidence: 99%

“…A cross-sectional design was applied in 9 studies 14,[17][18][19][20][21][22][23][24] , and an intervention design was used in the other 2 studies 15,16) . The intervention studies used the following treatment: a 9-week pharmacological approach (150 mg sustained-release bupropion twice daily) for non-specific subjects 15) and a 6-month nonpharmacological approach to quit smoking for patients with stable angina pectoris 16) .…”

Section: Study Designsmentioning

confidence: 99%

See 3 more Smart Citations

Adiponectin and Smoking Status: A Systematic Review

Kotani

Hazama

Hagimoto

et al. 2012

JAT

View full text Add to dashboard Cite

Aim:Smoking and adiponectin are individually associated with cardiometabolic pathologies. The present systematic review was carried out in order to summarize the association between the smoking status and circulating adiponectin levels. Methods: Original articles, restricted to epidemiological studies (by a cross-sectional, case-control and cohort study design) and intervention studies for adult humans, were screened for the years 1995-2010. All of the research group members then selected the eligible literature and assessed the articles in a structured systematic review manner. Results: There were 11 key studies, which included 9 articles with a cross-sectional design and 2 articles with an intervention design. Most cross-sectional studies reported lower levels of adiponectin in current smokers than in non/never smokers and/or ex-smokers, while 2 studies reported a non-significant difference in adiponectin between male smokers and non-smokers. The two intervention studies, conducted in patients on 9-week bupropion treatment and 6-month non-pharmacological treatment, reported that smoking cessation increased the adiponectin levels. Conclusion: This review suggests that there is a decreased adiponectin level in current smokers and this reduction can be reversed by quitting smoking. More studies are required to confirm the findings and elucidate the biological mechanisms underlying the association between the smoking status and adiponectin levels.

show abstract

Section: Gender Differencesmentioning

confidence: 99%

Section: Study Designsmentioning

confidence: 99%

Section: Measures Of Interestsmentioning

confidence: 99%

Section: Study Designsmentioning

confidence: 99%

See 2 more Smart Citations

Adiponectin and Smoking Status: A Systematic Review

Kotani

Hazama

Hagimoto

et al. 2012

JAT

View full text Add to dashboard Cite

show abstract

“…Adiponectin is an adipocyte-specific cytokine secreted from adipose tissue and plays an important negatively correlated with cardiovascular risk factors for ischemic heart disease, including hyperlipidemia 5) , hypertension 6) , and smoking 7) . Patients with coronary artery disease (CAD) were shown to have decreased plasma adiponectin concentrations 8) .…”

Section: Introductionmentioning

confidence: 99%

Association of Adiponectin with Future Cardiovascular Events in Patients After Acute Myocardial Infarction

Huang

Chen

et al. 2010

JAT

View full text Add to dashboard Cite

Aim:There is uncertainty about the association between circulating concentrations of adiponectin and coronary heart disease risk, particularly in patients after acute myocardial infarction (AMI). The goal of this study was to determine whether plasma adiponectin levels could predict future cardiovascular events in patients after AMI, and to elucidate the role of adiponectin in cardioprotection. Methods: A total of 102 patients with AMI were enrolled. Plasma adiponectin levels were examined from blood samples collected 18 months after AMI. All subjects were followed-up for 43 12 months. The primary endpoint was the combined occurrence of major adverse cardiovascular events (MACE), including rehospitalization due to unstable angina, nonfatal MI, revascularization with percutaneous coronary intervention or coronary artery bypass grafting, ischemic stroke, and cardiovascular death. Results: A total of 30 MACE occurred, including one case of cardiovascular death, five cases of nonfatal MI, and nine cases of ischemic stroke. Patients with MACE had lower plasma adiponectin levels (p 0.013). In addition, adiponectin was positively associated with changes in left ventricular ejection fraction (p 0.005). All patients were divided into a high-adiponectin group (≥ 6.46 g/mL) and a low-adiponectin group ( 6.46 g/mL). The incidence of MACE was significantly reduced in the high-adiponectin group (p 0.021). In multivariate Cox regression analysis that included adiponectin, classical risk factors, and medications, adiponectin was an independent predictor of MACE in patients after AMI (HR, 0.821; 95% CI, 0.691 to 0.974; p 0.024). Conclusions:The results indicate a potential association between plasma adiponectin levels and future cardiovascular events in patients after AMI. Moreover, plasma adiponectin concentrations appear to play a pivotal role in atherothrombosis and cardioprotection. J Atheroscler Thromb, 2010; 17:295-303.

show abstract

Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma

Vachher

Bansal

Kumar

et al. 2022

J of Cellular Biochemistry

View full text Add to dashboard Cite

Globally the incidence of hepatocellular carcinoma (HCC) is on an upsurge. Evidence is accumulating that liver disorders like nonalcoholic fatty liver disease (NAFLD) and its more progressive form nonalcoholic steatohepatitis (NASH) are associated with increased risk of developing HCC. NAFLD has a prevalence of about 25% and 50%–90% in obese population. With the growing burden of obesity epidemic worldwide, HCC presents a major healthcare burden. While cirrhosis is one of the major risk factors of HCC, available literature suggests that NAFLD/NASH associated HCC also develops in minimum or noncirrhotic livers. Therefore, there is an urgent need to understand the pathogenesis and risk factors associated with NAFLD and NASH related HCC that would help in early diagnosis and favorable prognosis of HCC secondary to NAFLD. Adipokines, hepatokines and myokines are factors secreted by adipocytes, hepatocytes and myocytes, respectively, playing essential roles in cellular homeostasis, energy balance and metabolism with autocrine, paracrine and endocrine effects. In this review, we endeavor to focus on the role of these organokines in the pathogenesis of NAFLD/NASH and its progression to HCC to augment the understanding of the factors stimulating hepatocytes to acquire a malignant phenotype. This shall aid in the development of novel therapeutic strategies and tools for early diagnosis of NAFLD/NASH and HCC.

show abstract

Smoking cessation increases serum adiponectin levels in an apparently healthy Greek population

Cited by 38 publications

References 24 publications

Adiponectin and Smoking Status: A Systematic Review

Adiponectin and Smoking Status: A Systematic Review

Association of Adiponectin with Future Cardiovascular Events in Patients After Acute Myocardial Infarction

Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma

Contact Info

Product

Resources

About